Floatz logo

BAY 59-7939

Venous Thrombosis

BayerDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Venous Thrombosis cohort.

Asset / SponsorPhaseRating
WARFARIN
Northern Jiangsu People's Hospital
Phase 4A
Apixaban
Northern Jiangsu People's Hospital
Phase 4BBB
Apixaban
Regeneron Pharmaceuticals
Phase 4BBB
Acetylsalicylic Acid
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BBB
NADROPARIN
Rijnstate Hospital
Phase 4BBB

View all 35 →

Same molecule, other indications

BAY 59-7939 is also rated in:

atrial fibrillationDormant
BB
Indicative ·
66 / 100
View asset →
Prevention & ControlDormant
BB
Indicative ·
64 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →